Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis
about
The importance of including amyopathic dermatomyositis in the idiopathic inflammatory myositis spectrumMeasures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-Modification of the cutaneous dermatomyositis disease area and severity index, an outcome instrument.Practice and Educational Gaps in Lupus, Dermatomyositis, and Morphea.Interstitial lung disease in classic and skin-predominant dermatomyositis: a retrospective study with screening recommendationsClinical outcome measures for cutaneous lupus erythematosus.Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment.Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life.Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis.A randomized, pilot trial of etanercept in dermatomyositis.Quality of life in dermatomyositis.Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change.The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measuresEvaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM.Comparison of the Utility and Validity of Three Scoring Tools to Measure Skin Involvement in Patients With Juvenile Dermatomyositis.Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research.Reliability and convergent validity of the cutaneous sarcoidosis activity and morphology instrument for assessing cutaneous sarcoidosis.Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease.Rheumatic manifestations of skin disease.Efficacy of low-dose methotrexate in the treatment of dermatomyositis skin lesions.Management of cutaneous dermatomyositis.Innate immune-response mechanisms in dermatomyositis: an update on pathogenesis, diagnosis and treatment.Evaluation of the reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index and the Cutaneous Assessment Tool-Binary Method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists.The reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) among dermatologists, rheumatologists and neurologists.Measurement of disease severity in cutaneous autoimmune diseases.213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18-20 September 2015Factors Associated With Clinical Remission of Skin Disease in Dermatomyositis.The systemic management of cutaneous dermatomyositis: Results of a stepwise strategy.Expanding the use of the Cutaneous Dermatomyositis Area and Severity Index (CDASI) to nondermatologists.Anti-transcription intermediary factor 1γ antibody titer correlates with clinical symptoms in a patient with recurrent dermatomyositis associated with ovarian cancer.Dysregulation of the type I interferon system in adult-onset clinically amyopathic dermatomyositis has a potential contribution to the development of interstitial lung disease.Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon β in dermatomyositis.Rapid increase of serum anti-MDA-5 antibodies and exacerbation of clinically amyopathic dermatomyositis/interstitial lung disease.
P2860
Q27014908-A391BECD-8C8D-4046-8535-0002D8AFE2DFQ27021322-9DE4A84F-E89F-42FC-88CD-FDCA4400C538Q33781378-4ACFE857-2913-4416-9502-DBF49A714990Q33913777-36483232-953A-4E6E-80E8-DC1BD807EEABQ34443730-5BFCBA3F-C803-4C28-A02C-223D6CE7D9C2Q34844623-BCA86A05-6371-48FE-9F27-932DBADC573EQ35009335-884E2B55-C235-4677-8075-710BE325BDDAQ35097253-ACC26C7E-BCBA-4FC4-A728-9BBC66E1664CQ35153899-A01530C7-7574-4DB8-967C-48E8A569D3E3Q35206687-C5E42CCD-E372-4A5E-ABF6-5FFEFA5F7E7FQ35293264-76746509-E83F-425E-9FA3-B969EA52AD67Q36932360-8938F839-E53B-45E0-90EC-2632F61634E5Q36949289-C9297BFD-22C6-4552-AF3D-63F4EE6AF4FCQ37118011-58C2F149-560C-4BB8-BD9D-26F3FA5F499DQ37316551-35404ABF-DD9E-485F-9F7D-CFA33B9413DAQ37368405-F87C3800-7993-4C92-A38B-98DF8A33F046Q37404210-C8A23DF2-4E4E-452F-9116-4E3D0ECD4EC6Q37579105-5E45EF36-C4E0-4F11-9136-B8B6FB23A8E3Q37620086-0C2FFC35-51E4-4137-82FD-BC3508F49700Q37943467-D675497A-374A-44BB-9C46-540DB6D5D671Q38022271-35D6A4B9-7780-415F-98CA-E17359A04DEFQ38221095-CD409CE9-5D8F-4131-A287-3CBB2001DD18Q38831077-E8BDCCBD-5D25-443D-9AE0-6C03616D5C6EQ39076011-09051C21-8FF2-48CE-80ED-8D0EE1FD4392Q41558860-164BB72A-4B27-45F9-8974-824E34D35866Q42365042-0CBE6A10-0BF6-4A50-BA04-18D02938BB71Q46134512-742CD318-F36B-432E-899C-85B64C6AC602Q47103957-BB14311F-5B87-4B6C-B53F-4FF2B94C2285Q48187148-69B5747C-1777-4433-86F1-9F3E684BDC07Q48227990-A1CEE16A-8B70-491E-B417-477EA0B58EFCQ51317487-1ECE6827-B8EC-4D79-8BD5-B6E2E9451000Q51549029-EA2DE32F-80A4-4148-8FCA-3E2F4F46CD29Q53817043-34DDC94E-A0E2-4105-9061-98FC8407183E
P2860
Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Comparison of the reliability ...... for cutaneous dermatomyositis
@ast
Comparison of the reliability ...... for cutaneous dermatomyositis
@en
type
label
Comparison of the reliability ...... for cutaneous dermatomyositis
@ast
Comparison of the reliability ...... for cutaneous dermatomyositis
@en
prefLabel
Comparison of the reliability ...... for cutaneous dermatomyositis
@ast
Comparison of the reliability ...... for cutaneous dermatomyositis
@en
P2093
P2860
P1476
Comparison of the reliability ...... for cutaneous dermatomyositis
@en
P2093
A Tanikawa
C A Bangert
M K Connolly
R D Sontheimer
P2860
P304
P356
10.1111/J.1365-2133.2008.08711.X
P407
P577
2008-07-04T00:00:00Z